Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 11, 2018 (9 years ago)

Ibuprofen Tablets USP 400 mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Ibuprofen Tablets USP 400 mg, 500 tablet bottles (NDC 42582-111-18), Rx, Distributed by Bi-Coastal Pharma International, Shrewsbury, NJ, Manufactured by: Marksans Pharma, Ltd., Plot No. L-82, L-83 Verna indl. Estate Verna, Goa-403 722, India

Affected NDC 42582-0111-18

Compare with the code on your package — it is the most precise check available.

Drug: Ibuprofen Category: Pain Relief & OTC Medication

Recalling firm
Time-Cap Laboratories, Inc.
NDC code
42582-111-18
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0688-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ibuprofen recalls

See all
Class II · Moderate risk

Advil a) Ibuprofen

CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.

Ongoing cGMP deviation Gold Star Distribution INC D-0261-2026
Class III · Low risk

IBU (ibuprofen)

Failed Tablet/Capsule Specifications

Ongoing Failed specification Dr. Reddy's Laboratories, Inc. NDC 55111-683-05 D-0047-2025
Class II · Moderate risk

Ibuprofen 800mg

Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.

Ongoing Impurity / degradation Direct Rx NDC 61919-0621-15 D-0041-2025

Other recalls by Time-Cap Laboratories, Inc.

All 2018 recalls
Class II · Moderate risk

Ibuprofen Caplets USP 200 mg

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Time-Cap Laboratories, Inc. NDC 53943-292-15 D-0695-2018
Class II · Moderate risk

Ibuprofen Caplets USP 200 mg

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Time-Cap Laboratories, Inc. NDC 49483-600-05 D-0694-2018
Class II · Moderate risk

Ibuprofen Tablets USP 800 mg

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Time-Cap Laboratories, Inc. NDC 42582-113-10 D-0693-2018
Class II · Moderate risk

Ibuprofen Tablets USP 800 mg

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Time-Cap Laboratories, Inc. NDC 49483-604-01 D-0692-2018